Global Neurodegenerative Diseases Drug Market Research Report 2022

Publisher Name :
Date: 03-Aug-2022
No. of pages: 87
Inquire Before Buying

Neurodegenerative Diseases Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

- By Drug Class

- - Immunomodulator

- - Interferons

- - Decarboxylase Inhibitors

- - Dopamine Agonists

- - Others

- By Route of Administration

- - Oral

- - Injection

- - Transdermal

Segment by Application

- Multiple Sclerosis

- Parkinson's Disease

- Alzheimer's Disease

- Spinal Muscular Atrophy (SMA)

- Others

By Region

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

By Company

- Biogen

- Pfizer

- Roche

- Novartis

- Sanofi

- Teva Pharmaceuticals

- Orion Pharma Ltd

- UCB S.A

- ACADIA Pharmaceuticals Inc.

- Lundbeck Pharmaceuticals Italy S.p.A.

- Mitsubishi Tanabe Pharma America

Global Neurodegenerative Diseases Drug Market Research Report 2022

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis By Drug Class
1.2.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate By Drug Class: 2017 VS 2021 VS 2028
1.2.2 Immunomodulator
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Drug Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Multiple Sclerosis
1.3.3 Parkinson's Disease
1.3.4 Alzheimer's Disease
1.3.5 Spinal Muscular Atrophy (SMA)
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Drug Market Perspective (2017-2028)
2.2 Neurodegenerative Diseases Drug Growth Trends by Region
2.2.1 Neurodegenerative Diseases Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neurodegenerative Diseases Drug Historic Market Size by Region (2017-2022)
2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Region (2023-2028)
2.3 Neurodegenerative Diseases Drug Market Dynamics
2.3.1 Neurodegenerative Diseases Drug Industry Trends
2.3.2 Neurodegenerative Diseases Drug Market Drivers
2.3.3 Neurodegenerative Diseases Drug Market Challenges
2.3.4 Neurodegenerative Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Drug Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2017-2022)
3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2017-2022)
3.2 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
3.4 Global Neurodegenerative Diseases Drug Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2021
3.5 Neurodegenerative Diseases Drug Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Drug Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Drug Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2017-2022)
4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2023-2028)
5 Neurodegenerative Diseases Drug Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Drug Historic Market Size by Application (2017-2022)
5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neurodegenerative Diseases Drug Market Size (2017-2028)
6.2 North America Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
6.3 North America Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Drug Market Size (2017-2028)
7.2 Europe Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
7.3 Europe Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size (2017-2028)
8.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
8.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Drug Market Size (2017-2028)
9.2 Latin America Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
9.3 Latin America Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size (2017-2028)
10.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2017-2022)
10.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Neurodegenerative Diseases Drug Introduction
11.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.1.5 Biogen Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.2.5 Pfizer Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Neurodegenerative Diseases Drug Introduction
11.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.3.5 Roche Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Neurodegenerative Diseases Drug Introduction
11.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.4.5 Novartis Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
11.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.5.5 Sanofi Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Detail
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
11.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Orion Pharma Ltd
11.7.1 Orion Pharma Ltd Company Detail
11.7.2 Orion Pharma Ltd Business Overview
11.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
11.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.7.5 Orion Pharma Ltd Recent Development
11.8 UCB S.A
11.8.1 UCB S.A Company Detail
11.8.2 UCB S.A Business Overview
11.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
11.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.8.5 UCB S.A Recent Development
11.9 ACADIA Pharmaceuticals Inc.
11.9.1 ACADIA Pharmaceuticals Inc. Company Detail
11.9.2 ACADIA Pharmaceuticals Inc. Business Overview
11.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
11.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.9.5 ACADIA Pharmaceuticals Inc. Recent Development
11.10 Lundbeck Pharmaceuticals Italy S.p.A.
11.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Detail
11.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
11.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
11.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
11.11 Mitsubishi Tanabe Pharma America
11.11.1 Mitsubishi Tanabe Pharma America Company Detail
11.11.2 Mitsubishi Tanabe Pharma America Business Overview
11.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
11.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2017-2022)
11.11.5 Mitsubishi Tanabe Pharma America Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Immunomodulator
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Drug Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Neurodegenerative Diseases Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Neurodegenerative Diseases Drug Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Drug Market Share by Region (2017-2022)
Table 11. Global Neurodegenerative Diseases Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Drug Market Share by Region (2023-2028)
Table 13. Neurodegenerative Diseases Drug Market Trends
Table 14. Neurodegenerative Diseases Drug Market Drivers
Table 15. Neurodegenerative Diseases Drug Market Challenges
Table 16. Neurodegenerative Diseases Drug Market Restraints
Table 17. Global Neurodegenerative Diseases Drug Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Drug Market Share by Players (2017-2022)
Table 19. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2021)
Table 20. Ranking of Global Top Neurodegenerative Diseases Drug Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Drug Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Drug Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Drug Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2017-2022)
Table 28. Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2023-2028)
Table 30. Global Neurodegenerative Diseases Drug Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2017-2022)
Table 32. Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2023-2028)
Table 34. North America Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2023-2028) & (US$ Million)
Table 44. Biogen Company Detail
Table 45. Biogen Business Overview
Table 46. Biogen Neurodegenerative Diseases Drug Product
Table 47. Biogen Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 48. Biogen Recent Development
Table 49. Pfizer Company Detail
Table 50. Pfizer Business Overview
Table 51. Pfizer Neurodegenerative Diseases Drug Product
Table 52. Pfizer Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 53. Pfizer Recent Development
Table 54. Roche Company Detail
Table 55. Roche Business Overview
Table 56. Roche Neurodegenerative Diseases Drug Product
Table 57. Roche Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 58. Roche Recent Development
Table 59. Novartis Company Detail
Table 60. Novartis Business Overview
Table 61. Novartis Neurodegenerative Diseases Drug Product
Table 62. Novartis Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. Sanofi Company Detail
Table 65. Sanofi Business Overview
Table 66. Sanofi Neurodegenerative Diseases Drug Product
Table 67. Sanofi Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 68. Sanofi Recent Development
Table 69. Teva Pharmaceuticals Company Detail
Table 70. Teva Pharmaceuticals Business Overview
Table 71. Teva Pharmaceuticals Neurodegenerative Diseases Drug Product
Table 72. Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 73. Teva Pharmaceuticals Recent Development
Table 74. Orion Pharma Ltd Company Detail
Table 75. Orion Pharma Ltd Business Overview
Table 76. Orion Pharma Ltd Neurodegenerative Diseases Drug Product
Table 77. Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 78. Orion Pharma Ltd Recent Development
Table 79. UCB S.A Company Detail
Table 80. UCB S.A Business Overview
Table 81. UCB S.A Neurodegenerative Diseases Drug Product
Table 82. UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 83. UCB S.A Recent Development
Table 84. ACADIA Pharmaceuticals Inc. Company Detail
Table 85. ACADIA Pharmaceuticals Inc. Business Overview
Table 86. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Product
Table 87. ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 88. ACADIA Pharmaceuticals Inc. Recent Development
Table 89. Lundbeck Pharmaceuticals Italy S.p.A. Company Detail
Table 90. Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
Table 91. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Product
Table 92. Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 93. Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
Table 94. Mitsubishi Tanabe Pharma America Company Detail
Table 95. Mitsubishi Tanabe Pharma America Business Overview
Table 96. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases DrugProduct
Table 97. Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2017-2022) & (US$ Million)
Table 98. Mitsubishi Tanabe Pharma America Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Drug Market Share by Type: 2021 VS 2028
Figure 2. Immunomodulator Features
Figure 3. Interferons Features
Figure 4. Decarboxylase Inhibitors Features
Figure 5. Dopamine Agonists Features
Figure 6. Others Features
Figure 7. Global Neurodegenerative Diseases Drug Market Share by Application in 2021 & 2028
Figure 8. Multiple Sclerosis Case Studies
Figure 9. Parkinson's Disease Case Studies
Figure 10. Alzheimer's Disease Case Studies
Figure 11. Spinal Muscular Atrophy (SMA) Case Studies
Figure 12. Others Case Studies
Figure 13. Neurodegenerative Diseases Drug Report Years Considered
Figure 14. Global Neurodegenerative Diseases Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 15. Global Neurodegenerative Diseases Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Neurodegenerative Diseases Drug Market Share by Region: 2021 VS 2028
Figure 17. Global Neurodegenerative Diseases Drug Market Share by Players in 2021
Figure 18. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drug as of 2021)
Figure 19. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Drug Revenue in 2021
Figure 20. North America Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. North America Neurodegenerative Diseases Drug Market Share by Country (2017-2028)
Figure 22. United States Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Neurodegenerative Diseases Drug Market Share by Country (2017-2028)
Figure 26. Germany Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Region (2017-2028)
Figure 34. China Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Japan Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. South Korea Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Southeast Asia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. India Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Australia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Latin America Neurodegenerative Diseases Drug Market Share by Country (2017-2028)
Figure 42. Mexico Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Brazil Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Country (2017-2028)
Figure 46. Turkey Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Saudi Arabia Neurodegenerative Diseases Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Biogen Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 49. Pfizer Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 50. Roche Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 51. Novartis Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 52. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 53. Teva Pharmaceuticals Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 54. Orion Pharma Ltd Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 55. UCB S.A Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 56. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 57. Lundbeck Pharmaceuticals Italy S.p.A. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 58. Mitsubishi Tanabe Pharma America Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2017-2022)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
  • Global Neurodegenerative Diseases Drug Market Research Report 2022
    Published: 03-Aug-2022        Price: US 2900 Onwards        Pages: 87
    Neurodegenerative Diseases Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - By Drug Class - - Immunomodulator - - Interfer......
  • (Post-pandemic Era) - Global Epilepsy Therapeutics Market Segment Research Report 2022
    Published: 02-Aug-2022        Price: US 3350 Onwards        Pages: 86
    Summary The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery. 2022 is a year of continuous recovery. Global supply chain disturba......
  • Post-pandemic Era - Global Epilepsy Therapeutics Market Analysis 2022, With Top Companies, Sales, Revenue, Consumption, Price and Growth Rate
    Published: 02-Aug-2022        Price: US 4860 Onwards        Pages: 83
    Summary The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery. 2022 is a year of continuous recovery. Global supply chain disturba......
  • Global Alcohol Addiction Therapeutics Market Research Report 2022
    Published: 07-Jul-2022        Price: US 2900 Onwards        Pages: 96
    Alcohol Addiction Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Alcohol Addiction Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - CM-1212 - CTDP-002 - A-705253 - ABT-436......
  • Global Epilepsy Therapeutic Market Research Report 2022
    Published: 01-Jul-2022        Price: US 2900 Onwards        Pages: 99
    Epilepsy Therapeutic market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Epilepsy Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - First Generation - Second Generation Segment by Application......
  • Global Epilepsy Therapeutics Market Research Report 2022
    Published: 29-Jun-2022        Price: US 2900 Onwards        Pages: 88
    Epilepsy Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Epilepsy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type - Anti-epileptic Drugs - Dietary Supplements - Vagal Nerve Stimulati......
  • Global and United States Epilepsy Therapeutics Market Report & Forecast 2022-2028
    Published: 13-Jun-2022        Price: US 4350 Onwards        Pages: 97
    Epilepsy Therapeutics market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Epilepsy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028. For United States market, this report focuses on the Epilepsy Therapeutics market size by pl......
  • Global and United States Restless Legs Syndrome Market Report & Forecast 2022-2028
    Published: 09-Jun-2022        Price: US 4350 Onwards        Pages: 92
    Restless Legs Syndrome market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Restless Legs Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028. For United States market, this report focuses on the Restless Legs Syndrome market......
  • 2022-2030 Report on Global Gabapentin Market by Player, Region, Type, Application and Sales Channel
    Published: 30-May-2022        Price: US 2500 Onwards        Pages: 117
    This report studies the Gabapentin market, covering market size for segment by type (Capsule, Tablet, etc.), by application (Epilepsy, Neuropathic Pain, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Pfizer, Depomed, TEVA, Mylan, Arbor Pharma, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Gabapentin from 2016-2021, and provides ext......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs